Taiko Pharmaceutical
4574.TPharmaceutical
Filed as TAIKO PHARMACEUTICAL CO.,LTD. (2022-08–2026-08)
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥6.4bn | ¥6.3bn | ¥6.1bn | ¥5.0bn | ¥11.3bn | ¥17.6bn |
| Operating income | ¥459m | ¥629m | −¥1.0bn | −¥3.1bn | −¥4.9bn | — |
| Ordinary income | ¥482m | ¥688m | −¥1.2bn | −¥3.4bn | −¥6.1bn | ¥5.5bn |
| Net income (owners) | ¥923m | ¥898m | −¥3.6bn | −¥4.9bn | −¥9.6bn | ¥3.9bn |
| Total assets | ¥12.3bn | ¥12.9bn | ¥13.2bn | ¥15.0bn | ¥22.5bn | ¥31.8bn |
| Net assets / equity | ¥8.5bn | ¥8.0bn | ¥6.7bn | ¥8.0bn | ¥12.8bn | ¥22.8bn |
| Operating cash flow | ¥814m | ¥362m | −¥307m | −¥2.0bn | −¥1.6bn | −¥1.5bn |
| EPS (basic) | ¥18.38 | ¥17.9 | ¥-76.25 | ¥-112.26 | ¥-220.52 | ¥89.18 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 71 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 199 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 71 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 201 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 71 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 47 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 204 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 49 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 47 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 207 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 49 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 73 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Infection Control Business | ¥619m | −¥254m |
| Pharmaceuticals Business | ¥5.8bn | ¥1.6bn |
| Other segments | ¥5m | −¥22m |
| Adjustments & eliminations | — | −¥837m |
| Total | ¥6.4bn | ¥1.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.